Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours by unknown
Inagaki et al. Clin Sarcoma Res  (2016) 6:13 
DOI 10.1186/s13569-016-0053-3
RESEARCH
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Abstract 
Background: A chronic inflammatory cell infiltrate is commonly seen in response to primary malignant tumours of 
bone. This is known to contain tumour-associated macrophages (TAMs) and lymphocytes; dendritic cells (DCs) and 
mast cells (MCs) have also been identified but whether these and other inflammatory cells are seen commonly in 
specific types of bone sarcoma is uncertain.
Methods: In this study we determined the nature of the inflammatory cell infiltrate in 56 primary bone sarcomas. 
Immunohistochemistry using monoclonal antibodies was employed to assess semiquantitatively CD45+ leukocyte 
infiltration and the extent of the DC, MC, TAM and T and B lymphocyte infiltrate.
Results: The extent of the inflammatory infiltrate in individual sarcomas was very variable. A moderate or heavy 
leukocyte infiltrate was more commonly seen in conventional high-grade osteosarcoma, undifferentiated pleomor-
phic sarcoma and giant cell tumour of bone (GCTB) than in Ewing sarcoma, chordoma and chondrosarcoma. CD14+/
CD68+ TAMs and CD3+ T lymphocytes were the major components of the inflammatory cell response but (DC-SIGN/
CD11c+) DCs were also commonly noted when there was a significant TAM and T lymphocyte infiltrate. MCs were 
identified mainly at the periphery of sarcomas, including the osteolytic tumour-bone interface.
Discussion: Our findings indicate that, although variable, some malignant bone tumours (e.g. osteosarcoma, GCTB) 
are more commonly associated with a pronounced inflammatory cell infiltrate than others (e.g. chondrosarcoma. 
Ewing sarcoma); the infiltrate is composed mainly of TAMs but includes a significant DC, T lymphocyte and MC 
infiltrate.
Conclusion: Tumours that contain a heavy inflammatory cell response, which includes DCs, TAMs and T lymphocytes, 
may be more amenable to immunomodulatory therapy. MCs are present mainly at the tumour edge and are likely to 
contribute to osteolysis and tumour invasion.
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Background
Host defence against primary bone sarcomas is evidenced 
by the presence of a chronic inflammatory cell infil-
trate both within the tumour and in the ‘pseudocapsule’ 
around the tumour [1, 2]. The inflammatory cell response 
to malignant tumours, including sarcomas, is composed 
mainly of tumour-associated macrophages (TAMs) 
and lymphocytes, but is known to include dendritic 
cells (DCs) and mast cells (MCs) [2–5]. Tumour cells 
and stromal cells in the tumour microenvironment are 
known to release chemokines, cytokines and growth fac-
tors which attract inflammatory cells; these cells in turn 
release numerous humoral factors that are implicated in 
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promoting tumour growth, angiogenesis and modulation 
of the immune response [5, 6].
The cellular components of the peri-tumoural inflam-
matory infiltrate reflect the nature of the innate and 
adaptive host immune response to a particular tumour. 
Specific inflammatory cell components have been shown 
to produce both positive and negative effects on tumour 
growth and spread. In some cancers, a high TAM infil-
trate has been shown to correlate with poor prognosis, 
leading to the suggestion that these cells could represent 
a potential therapeutic target for cancer immunotherapy 
[7–9]. In contrast, lymphocytic infiltration, predomi-
nantly of T lymphocytes, correlates with improved sur-
vival in several cancers [10–12]. The role of other myeloid 
cells known to be present in cancer-related inflammation, 
such as DCs and MCs, is less well-defined. Some but by 
no means all studies have shown that DC infiltration of 
carcinomas is associated with increased survival and 
reduced incidence of metastasis; accordingly, immuno-
therapeutic strategies to treat solid tumours have been 
developed that exploit the specific role of DCs to coor-
dinate the innate and adaptive immune response [13, 14]. 
MCs have been shown to play a role in regulating the 
adaptive immune response and in mediating vascular and 
stromal changes in tumour tissues [4, 15, 16]. MCs have 
also been shown to influence the extent of the DC, TAM 
and lymphocyte infiltrate through the release of media-
tors which enhance migration and proliferation of these 
cells [17–20].
Although immunotherapies targeting TAMs, lympho-
cytes and DCs have been investigated in some bone and 
soft tissue sarcomas [21–24], there has been little analy-
sis of the number of these inflammatory cells in specific 
primary malignant bone tumours. In this study our aim 
has been to examine the nature and extent of myeloid 
and lymphoid inflammatory cells found in different types 
of primary malignant bone tumour. In this way we have 
sought to determine not only whether TAMs, lympho-
cytes, DCs and MCs are likely to play a role in influencing 
tumour growth and spread but also whether these cells 
are present in sufficient numbers to provide a target for 
immunotherapy in specific sarcomas.
Methods
Cases examined and specimen processing
Samples of 56 primary malignant bone tumours were 
obtained from archival surgical material at the Depart-
ment of Histopathology, Nuffield Orthopaedic Centre, 
Oxford, UK. Samples of primary aggressive or malignant 
bone tumours included 14 cases of conventional osteo-
sarcoma, 8 cases of Grade I chondrosarcoma, 4 cases of 
Grade II/III chondrosarcoma, 2 cases of dedifferentiated 
chondrosarcoma, 11 cases of giant cell tumour of bone 
(GCTB), 12 cases of Ewing sarcoma, 2 cases of chordoma 
and 3 cases of undifferentiated pleomorphic sarcoma of 
bone. None of the patients had received immunomodula-
tory neo-adjuvant therapies.
Several osteolytic benign bone tumours were also 
assessed for MC infiltration. These included 4 cases of 
fibrous dysplasia, 4 cases of non-ossifying fibroma, 2 
cases of osteoblastoma, 2 cases of aneurysmal bone cyst 
and 2 cases of chondroblastoma.
Control tissues included samples of normal bone 
obtained from amputation specimens and, for mast cell 
staining, samples of bone obtained from two cases of 
systemic mastocytosis. All samples were fixed in 10  % 
neutral buffered formalin and decalcified in 5  % nitric 
acid prior to processing and embedding in paraffin wax. 
Serial sections of 5 µm were cut and mounted on charged 
microscope slides (Surgipath, UK) for immunohisto-
chemical staining.
Immunohistochemistry
Monoclonal antibodies employed in this study and their 
specificity are shown in Table 1. Sections were incubated 
at 37 °C for at least 24 h to improve tissue adhesion before 
immunohistochemistry. Tissue sections were dewaxed in 
xylene and rehydrated by successive immersion in graded 
alcohol and water. Endogenous peroxidase was blocked 
by treating the sections with 0.2  % hydrogen peroxide 
(BDH, UK) in 80 % alcohol for 30 min. Antigen retrieval 
was required for all antibodies. This involved microwave 
heat treatment in 500 ml 10 mM Tris/1 M EDTA (BDH, 
UK) buffer, pH 8.5.
Immunohistochemistry was performed using an indi-
rect immunoperoxidase technique with 3,3-diaminoben-
zidine chromogen (ChemMate Envision, Dako, UK). 
Sections were incubated with primary antibodies for 
30  min at room temperature followed by 30  min incu-
bation with labelled polymer and 10 min in 3,3-diamin-
obenzidene. The sections were then counterstained using 
Mayer’s haematoxylin (RA Lamb, UK) for 3  min and 
blued in 2 % hydrogen sodium carbonate (BDH, UK).
Histological analysis
Areas of tumour containing the maximum inflamma-
tory response were scored, as previously described, by a 
modified semi quantitative technique as sparse (<2  %), 
moderate (2–10 %) or dense (>10 %) after counting 500 
cells in five high-powered (×400) fields and determining 
the number of cells expressing CD45 (leukocyte com-
mon antigen) [25, 26]. Areas of tumour necrosis were not 
included in this assessment. In parallel sections stained 
with immunophenotypic markers, identifying B and T 
lymphocytes, TAMs, MCs and DCs (Table 1), the num-
ber of these infiltrating cells was scored relative to the 
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number of CD45+  cells as:  +low (<5  % positive cells); 
++moderate (6–25 % positive cells); +++heavy (>25 % 
positive cells).
Results
Results of the immunohistochemical findings are sum-
marised in Table 2.
The extent of the CD45+ inflammatory cell infiltrate in 
the malignant bone tumours analysed was highly varia-
ble, not only between different types of bone sarcoma but 
also between sarcomas of a single type. The inflammatory 
infiltrate was not uniformly distributed throughout these 
tumours; all GCTBs contained a dense CD45+  inflam-
matory infiltrate while osteosarcoma and undifferenti-
ated pleomorphic sarcomas often contained areas with 
a moderate CD45+  infiltrate (Fig. 1). In contrast, chon-
drosarcomas, chordomas and Ewing sarcomas contained 
a sparse inflammatory cell infiltrate. In all bone sarcomas, 
CD68+  TAMs comprised the largest sub-population of 
inflammatory cells in the tumour followed by CD3+  T 
cells and DCs. CD20+ B cells were absent or very rarely 
identified in the bone sarcomas analysed.
Where there was a high number of CD68+ TAMs and 
CD3+  T lymphocytes in bone sarcomas, DC-SIGN-
expressing DCs were noted; some of these cells stained 
for CD11c and S100 but they did not stain for CD1a. The 
most common pattern seen in conventional osteosar-
coma, undifferentiated pleomorphic sarcoma and GCTB 
was that of a moderate or heavy (++/+++) TAM infil-
trate, with a low/moderate (+/++) CD3+ T cell and DC 
infiltrate (Fig. 2). DCs were absent or present in low num-
bers (+) in chondrosarcoma, chordoma and most but 
not all Ewing sarcomas. All Grade 1 chondrosarcomas 
contained a sparse inflammatory cell infiltrate (Fig.  3a). 
A few (+) TAMs were noted in areas of matrix degen-
eration or mineralisation but there were few or no T cells 
or DCs identified in the tumour stroma. Grade II and III 
chondrosarcomas also contained few or no inflammatory 
cells, although some TAMs, T cells and DCs were seen in 
areas of matrix degeneration in fibrous tissue separating 
lobules of tumour cartilage. DCs were not present in the 
low-grade cartilaginous component but were seen in the 
spindle cell component of dedifferentiated chondrosar-
coma (Fig. 3c). These tumours also contained numerous 
TAMs and T cells.
MCs were not present or very few in number in the 
main tumour mass of most bone sarcomas. However, 
MCs (+/++) were commonly found at the periphery of 
invasive bone tumours in the fibrous pseudocapsule at 
the soft tissue margin and at the host bone-tumour inter-
face where there was osteolysis (Fig.  4). The finding of 
an MC association with tumour osteolysis in sarcomas 
prompted us to examine MC infiltration in lytic benign 
bone tumours. We found that MCs were commonly sited 
at the host bone-tumour interface in all cases of chondro-
blastoma (Fig. 4d), osteoblastoma, aneurysmal bone cyst, 
Table 1 Monoclonal antibodies used in this study
MW microwave, – no pre-treatment required
Antigen Antibody (clone) Specificity Source Dilution Pre-treatment
CD3 (F7.2.38) T cells Dako 1:25 MW 20 min
CD11c (5D11) DCs, histiocytes Novocastra 1:100 MW 20 min
CD14 (7) Macrophages, monocytes Novocastra 1:50 MW 20 min
CD20 (L26) B cells Dako 1:100 ─
CD45 (PD7/26;2B11) Leucocyte common antigen Dako 1:100 MW 10 min
CD68 (KP1) Macrophages, monocytes, neutrophils, NK cells Dako 1:1000 MW 10 min
DC-SIGN (120,507) Immature DCs R&D Systems 1:500 MW 10 min
S100 (polyclonal) DCs, histiocytes, chondrocytes Dako 1:1000 ─
Mast cell tryptase AA1 Mast cells Dako 1:100 MW 10 min
Table 2 Tumour-infiltrating leucocyte antigen expression
Inter/intra-tumour variability of leucocyte antigen expression noted. For details, see “Results” section
a Mast cells (+/++) were identified at the periphery of all osteolytic bone tumours
CD45 CD68 CD14 CD3 CD20 DC-SIGN Mast cella tryptase
Giant cell tumour of bone Dense +++ ++ + – + +/++
Osteosarcoma; Undifferentiated pleomorphic sarcoma dedifferentiated 
chondrosarcoma
Moderate ++ +/++ + – + +/++
Ewing sarcoma Chondrosarcoma Chordoma Sparse +/++ +/++ −/+ – −/+ +/++
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non-ossifying fibroma and fibrous dysplasia. A few (+) 
MCs were also noted in fibrotic areas of undifferentiated 
pleomorphic sarcomas and osteosarcomas of bone. MCs 
(++) were also commonly seen in the fibrous component 
of benign bone lesions such as non-ossifying fibroma and 
fibrous dysplasia.
Fig. 1 Immunohistochemistry for the leucocyte marker CD45 showing that the inflammatory cell infiltrate is: a heavy in GCTB. b Moderate in 
osteosarcoma. c Sparse in Ewing sarcoma
Fig. 2 Immunohistochemistry for the DC marker for DC-SIGN showing: a moderate (++) expression in GCTB. b Low (+) expression in osteosar-
coma. c Absence of expression in Ewing sarcoma
Fig. 3 Immunohistochemistry for the macrophage marker CD68 in chondrosarcoma showing: a absence of TAMs in low-grade chondrosarcoma. 
b Scattered (+) TAMs in areas of matrix mineralisation within the tumour. c Absence of TAMs in the low-grade cartilaginous component (left) but 
scattered (+) TAMs in the high-grade sarcomatous component (right) of a dedifferentiated chondrosarcoma
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Discussion
This study has shown that myeloid and lymphoid cells, 
which play a role in innate and adaptive immunity are 
present in the inflammatory response to primary aggres-
sive/malignant bone tumours. A significant inflamma-
tory cell infiltrate was commonly seen in osteosarcoma, 
undifferentiated pleomorphic sarcoma, GCTB and dedi-
fferentiated chondrosarcomas. Inflammation was less 
pronounced in Ewing sarcoma, chordoma and chon-
drosarcoma. TAMs formed the major component of the 
inflammatory cell infiltrate in all bone tumours; there 
was also a variable population of CD3+ T cells and DCs. 
In general, the extent of DC infiltration corresponded to 
that of TAMs and T cells. MCs were found mainly at the 
osteolytic bone-tumour interface in bone sarcomas as 
well as other benign primary bone tumours.
As in carcinomas and soft tissue sarcomas, the major 
subpopulation of leukocytes noted in bone sarcomas was 
that of TAMs [5, 26]. TAMs have been shown to promote 
tumour progression in several carcinomas by suppressing 
the immune response, increasing expression of matrix 
metalloproteinases and promoting tumour angiogenesis 
[5, 7–9]. The role of TAMs in bone sarcomas has not 
been extensively investigated. TAMs have been associ-
ated with reduced metastasis and improved survival in 
high-grade osteosarcoma [30]. In contrast, TAM infiltra-
tion has been associated with a poor prognosis in Ewing 
sarcoma [31]. Osteoclasts, which carry out the bone 
resorption associated with growth of a bone tumour are 
derived from TAMs by a RANKL-dependent mechanism 
[32, 33], and it would be expected that a heavy TAM 
infiltrate would promote tumour growth and spread. 
Ewing sarcoma and osteosarcoma tumour cells have been 
shown to express RANKL and to support macrophage-
osteoclast differentiation [33–36]. Although we found 
that the majority of Ewing sarcomas in our study induced 
a relatively low inflammatory cell response, we noted that 
most of the cells in the infiltrate were TAMs. Paradoxi-
cally, it has been shown in some reports that there is an 
inverse relationship between the number of osteoclasts 
Fig. 4 Immunohistochemistry for mast cell tryptase showing MCs in: a the pseudocapsule and b tumour-bone interface of an osteosarcoma. c The 
soft tissue margin of an aggressive GCTB. d The osteolytic margin of a chondroblastoma
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and the extent of pulmonary metastasis [37, 38]. Fur-
ther studies are required to establish the role of TAMs 
in high-grade bone sarcomas as these cells constitute 
the major subpopulation of inflammatory cells in these 
tumours.
DCs and CD3+  T lymphocytes were noted in all 
types of bone sarcoma and in general their number cor-
responded with the extent of TAM infiltration. DCs 
are efficient antigen-presenting cells that have the abil-
ity to prime naïve T cells and initiate a specific immune 
response [37, 38]. DCs exist in two functionally and 
phenotypically distinct stages, immature and mature. 
Immature DCs have high endocytic activity, specialise 
in antigen capture and processing and reside in periph-
eral tissues. Upon exposure to pathogen-derived prod-
ucts or innate pro-inflammatory signals, DCs lose their 
phagocytic activity and migrate to draining lymph nodes 
where they become mature DCs. Mature DCs have high 
antigen-presenting capability and interact with antigen-
specific T cells to initiate a specific immune response. 
In tumours there is a disturbance of DC differentiation, 
survival and function [13, 14, 38]. A C-type lectin, a 
DC-specific ICAM-grabbing non-integrin (DC-SIGN), 
has been identified and shown to mediate strong adhe-
sion between DCs and intracellular adhesion molecule 
3 (ICAM-3) on resting T cells [39, 40]. We noted that 
CD3+  T lymphocytes were more commonly found in 
osteosarcomas than Ewing sarcomas although consider-
able variation was observed regarding the density and 
distribution of these cells, some of which have been 
shown to be cytotoxic against osteosarcoma tumour cells 
and to promote adaptive antitumor immunity in Ewing 
sarcoma [41, 42]. Tumour-derived factors such as vascu-
lar endothelial growth factor can induce immature DCs 
from the bone marrow to migrate to osteosarcomas [43, 
44]. Although showing some variability, fewer DCs were 
seen in Ewing sarcomas where the TAM and T-lympho-
cyte response was also reduced. The suppression of DC 
antigen and function can induce immune tolerance to 
tumour antigens in sarcomas [39]; specifically, the alter-
ation of carbohydrates on the cell surface is thought to 
influence the interaction between C-type lectins on DCs 
and tumour cells, thus interfering with antigen presen-
tation [45]. DC-SIGN is a useful immunohistochemical 
marker of immature and mature DCs and may be use-
ful in assessing the efficacy of DC-based immunotherapy 
against sarcomas [46, 47]. Antibodies targeting DC-SIGN 
have been used to induce a T cell response, and vaccines 
comprising autologous antigen-loaded DCs have been 
shown to prime tumour immunity [48, 49].
MCs are found throughout the body and are usually 
located in connective tissues, particularly around blood 
and lymphatic vessels as well as peripheral nerves; they 
are present in low numbers in normal human bone mar-
row [50]. MCs are mobilised to infiltrate tumours by 
means of stem cell factor (SCF) [16, 18]. Production of 
SCF and the receptor for SCF (c-kit) have been identi-
fied in several bone sarcomas, including Ewing sarcoma 
and osteosarcoma [51–53]. Mechanisms whereby MCs 
may influence tumour progression include stimulation of 
the release of growth factors essential for tumour growth 
and suppression of the host immune response to tumour 
cells [16, 18]. MC-derived humoral factors are known to 
influence the migration and function of TAMs, T-lym-
phocytes and DCs [18–20]. We noted that MCs were 
found mainly at the tumour-bone interface where there 
was tumour-associated osteolysis. MCs have been iden-
tified at the periphery of tumours in aggressive breast 
cancer and malignant melanoma [16]. MCs are known to 
promote osteoclastic bone resorption and to play a role 
in inflammatory osteolysis, renal osteodystrophy and 
other bone conditions where there is increased remodel-
ling activity [50, 54]. Mediators produced by MCs which 
promote osteoclastic resorption include the prostaglan-
dins E2 and D2, and cytokines such as tumour necrosis 
factor alpha (TNFα) [16, 19]. The latter has been shown 
to simulate osteoclast formation by a RANKL-independ-
ent mechanism [55], it has been shown that TAM-oste-
oclast differentiation in Ewing sarcoma can be induced 
by TNFα [33]. This may play a role in promoting tumour 
metastases in Ewing sarcoma which is modulated by 
stem cell factor and its receptor c-kit [56].
Conclusions
Our findings show that the inflammatory response 
to primary malignant bone tumours is variable and 
to some extent depends on tumour type. TAMs and 
T-lymphocytes are the major inflammatory cell types 
seen in bone sarcomas but there is also a significant 
DC component within some tumours. MCs are likely 
to contribute to tumour osteolysis as they are almost 
exclusively found at the tumour-bone interface. Using 
specific myeloid and lymphoid inflammatory cell sub-
populations as targets for immunomodulatory therapy 
has been proposed for bone sarcomas but the efficacy 
of such treatment is likely to depend of the presence of 
a significant inflammatory response in the tumour; our 
findings show that this can be highly variable, and it 
may thus be useful to assess the extent and nature of the 
inflammatory cell response in a bone sarcoma before 
instituting this type of therapy.
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